Academic Press Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance

Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers. Review Provides a complete reference on the development of the translational applications of NK immunotherapy in human cancer patients From the Back Cover Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the very novel and unique therapeutic applications of NK cells to fight cancers and, primarily, eliminate both the bulk and the subset of cancer stem cells responsible for metastasis, relapse and recurrences. It provides up to date information on the development, engineering, mechanisms of action, response to various preclinical models, and current applications in various clinical trials. The book covers the state of the art on the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, as well as new NK-drug conjugates in order to potentiate their anti-tumor activities. In addition, the book emphasizes that, unlike other immunotherapeutic approaches, the activated NK cells can also target and kill the highly resistant cancer stem cells that are responsible for the relapses and recurrences by all other therapeutic treatments. Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians, and members of biomedical field who are interested in understanding novel and efficient therapies to fight cancers. About the Author Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy, “Breaking Cancer Resistance to Therapeutic Antibodies, and “Breaking Tolerance to Anti-Cancer Immunotherapy) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett. Dr. Anahid Jewett, PhD, MPH, is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She serves on the editorial board of many prestigious journals and has been a reviewer on the board of National Institute of Health study sections. She holds several patents and has published more than 100 high impact journal articles, reviews, commentaries and book chapters in the field of cancer. Dr. Jewett’s major contributions to science and NK cell biology were the identification, characterization and the establishment of the concept of split